What Researchers Did
Researchers conducted a comprehensive review of experimental and clinical trials investigating hyperbaric oxygen therapy (HBOT) as a supplementary treatment for inflammatory bowel diseases (IBD).
What They Found
The review found that hyperbaric oxygen therapy (HBOT) may offer therapeutic benefits for inflammatory bowel diseases (IBD) by decreasing oxidative stress and inhibiting mucosal inflammation. Additionally, HBOT was shown to promote ulcer healing, influence gut microbes, and potentially reduce the incidence of IBD complications.
What This Means for Canadian Patients
For Canadian patients with inflammatory bowel diseases, this review suggests that hyperbaric oxygen therapy could potentially serve as an adjunctive treatment option. Patients should discuss with their healthcare providers whether HBOT might be a suitable supplement to their current IBD management plan.
Canadian Relevance
This review does not have a direct Canadian connection, as it synthesizes global research on hyperbaric oxygen therapy for inflammatory bowel diseases.
Study Limitations
As a review, this study synthesizes existing literature and does not present new primary data or direct patient outcomes from novel research.